---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013051"
form_type: "8-K"
ticker: null
cik: "0001173281"
company_name: "NeuBase Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:17:27.456028+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeuBase halts program development, cuts 83% workforce, explores strategic alternatives

## Summary
- Workforce reduced by ~83%; estimated $400K in severance and termination costs.
- Board halts further development of all programs, including Stealth Editors gene editing candidates.
- Company will explore strategic alternatives: acquisition, merger, business combination, or other transaction.
- No timetable set for evaluation; no assurance that any transaction will be completed.
- Decision not related to safety issues or negative regulatory feedback; cost-cutting focus.

## SEC filing metadata
- accession: 0001558370-23-013051
- form_type: 8-K
- cik: 0001173281
- company_name: NeuBase Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/0001558370-23-013051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/nbse-20230728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013051
- JSON: https://secwatch.observer/filing/0001558370-23-013051.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013051.txt

## Key facts
- Restructurings & Charges
  NeuBase Therapeutics, Inc. announced a restructuring with charges of approximately $400,000 affecting different areas and functions (approximately 83%).
  - Type: restructuring
  - Charge: approximately $400,000
  - Affected area: different areas and functions
  - Headcount: approximately 83%
  source text: compensation grants and continuation of group health insurance coverage for a specified period to the affected employees. The Company estimates that it will incur approximately $400,000 of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The costs related to the Restructuring are subject to a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/0001558370-23-013051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.